NCT06964737View on ClinicalTrials.gov

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaWHO Grade 2 GliomaWHO Grade 3 GliomaWHO Grade 4 Glioma
Interventions
BIOLOGICAL

Anti-GARP Chimeric Antigen Receptor-T Cells

Given intracavitary

PROCEDURE

Biospecimen Collection

Undergo collection of CSF and blood samples

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Pheresis

Undergo apheresis

PROCEDURE

Surgical Procedure

Undergo surgery and placement of CSF reservoir

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER